Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.

NCT01879319 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01879319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01879319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
July 11, 2013
Completion date
Not reported
Enrollment
164 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

mixed dyslipidemia, primary hypercholesterolemia